Update your settings

Multinational esports organisation Gaimin Gladiators has announced a three-year partnership renewal with esports analytics company Shikenso.

As a result of the renewal, the analytics firm will continue to provide the organisation with marketing metrics that can be offered to sponsors.

• Gaimin Gladiators looks to bolster commercial portfolio with EPIC Global
• Shikenso Analytics launches ‘Esports Radar’
• Italian Taekwondo Federation launches national esports team

Gaimin Gladiators claimed it generated 5bn media impressions in 2022, with this expected to increase to 10bn media impressions in 2023. These figures, which were measured using the help of Shikenso, enable Gaimin Gladiators to demonstrate the visibility of its sponsor brand assets across all media streaming platforms.

Shikenso also said its services allow Gaimin Gladiators to deliver ‘appropriate analysis’, such as per team, per event, and per player impressions to help bolster brand visibility and other partner opportunities.

Gaimin Gladiators have become a prominent esports organisation within the DOTA 2 scene since its foundation in 2022. This year alone the organisation has won two Majors — Lima Major 2023 and ESL One Berlin Major 2023 — as well as DreamLeague Season 19.

Some of the organisation’s partners include the likes of blockchain company BNB Chain, bookmaker Kaiyun, and PC builder Stoneforged Technology. In August 2022, Gaimin Gladiators signed a deal with esports agency EPIC Global to help assist the organisation with commercial partnerships.

Alexander Cuccovillo, Gaimin Gladiators Vice President and Co-Founder, commented: “We are delighted to continue our partnership with Shikenso. Over the last year, we have worked closely with them allowing us to demonstrate what we can provide to partners as well as future partners. 

“They have some of the best technology in the business and couldn’t be happier with their product and the staff behind them.

Alongside Gaimin Gladiators, Shikenso’s clients include Team Vitality, Astralis and SQVAD, among others.